Dose modification and safety
acneiform rash, paronychia, rash, skin toxicities
ADVERSE EVENTS, ADVERSE EVENT, PARONYCHIA, SKIN TOXICITIES
Due to skin toxicities, eight patients (19.5%; 95% CI, 7.4%–31.6%) underwent dose reduction. Of the eight patients, seven reduced the dacomitinib dosage once and one reduced the dose twice. The reasons for dose reduction mainly included acneiform rash (six patients), maculopapular rash (three patients), and paronychia (two patients).In addition to skin toxicities, severe non‐hematological adverse events (Grade ≥3) occurred in 12 patients (29.3%) (Table Adverse events other than skin toxicities in the initial 8 weeks of treatment (Number of evaluated population = 40 patients.Number of evaluated population = 37 patients.